Skip to main content

Table 5 Summary of phase 3 trials of sofosbuvir and ledipasvir in hepatitis C virus genotype 1

From: Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Study

Population

Treatment/Duration

SVR12 rates

ION-1

HCV GT1 treatment-naïve including 15.7% (136/865) with cirrhosis

SOF/LDV, 12 weeks

97.7% (209/214)

  

SOF/LDV + RBV, 12 weeks

97.2% (211/217)

  

SOF/LDV, 24 weeks

NA (n = 217)

  

SOF/LDV + RBV, 24 weeks

NA (n = 217)

ION-2

HCV GT 1 treatment-experienced including 20.0% (88/440) with cirrhosis

SOF/LDV, 12 weeks

93.6% (102/109)

  

SOF/LDV+RBV, 12 weeks

96.4% (107/111)

  

SOF/LDV, 24 weeks

99.1% (108/109)

  

SOF/LDV+RBV, 24 weeks

99.1% (110/111)

ION-3

HCV GT1 treatment-naïve

SOF/LDV, 8 weeks

94.0% (202/215)

  

SOF/LDV + RBV, 8 weeks

93.1% (201/216)

  

SOF/LDV, 12 weeks

95.4% (206/216)

  1. SVR: Sustained virologic response. HCV: Hepatitis C virus. GT: Genotype. SOF: Sofosbuvir. LDV: ledipasvir. RBV: ribavirin. NA: not available.